This Article Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Merke, D. P. Articles by Chrousos, G. P. Search for Related Content PubMed PubMed Citation Articles by Merke, D. P. Articles by Chrousos, G. P.

Hydrocortisone Suspension and Hydrocortisone Tablets Are Not Bioequivalent in the Treatment of Children with Congenital Adrenal Hyperplasia

Warren Grant Magnuson Clinical Center (D.P.M., D.C., K.A.C.), Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development (D.P.M., M.F.K., G.P.C.), National Institutes of Health, Bethesda, Maryland

Abstract

In July 1998, Cortef oral suspension (Pharmacia & Upjohn) was reformulated changing the suspending agent tragacanth to xanthan gum. We subsequently observed suboptimal control of hormone levels in a group of children with classic congenital adrenal hyperplasia, despite increasing doses of Cortef suspension and stringent instructions to parents regarding shaking of the bottles of medication. Nineteen children receiving Cortef and fludrocortisone therapy were changed to hydrocortisone tablets and fludrocortisone, with a 10 percent reduction in hydrocortisone dose. A significant decrease in 17-hydroxyprogesterone (235 ± 120 vs. 27 ± 7 nmol/L; p0.001) and androstenedione (18.9 ± 18.0 vs. 3.5 ± 3.5 nmol/L; p=0.002) was observed 4–6 weeks later. Twenty-one percent (4/19) had 17-hydroxyprogesterone and androstenedione levels at or below the detection limit of the assay. Despite a significant reduction in glucocorticoid dose (19.6 ± 4.7 vs. 17.6 ± 3.9 mg/M²/day; p<0.001), eight children experienced significant weight gain and appetite increase, three experienced trouble sleeping, four experienced moodiness, and three developed hypertension requiring a decrease in fludrocortisone therapy. Hydrocortisone dose was further decreased to 15.2 ± 2.6 mg/M²/day with resolution of symptoms. We conclude that Cortef suspension and hydrocortisone tablets are not bioequivalent and the reformulated form of hydrocortisone oral suspension was inadequate in the control of children with congenital adrenal hyperplasia. Cortef suspension has been recalled as a result of these data.

This article has been cited by other articles:

				A. M. Maguire, G. R. Ambler, B. Moore, M. McLean, M. G. Falleti, and C. T. Cowell Prolonged Hypocortisolemia in Hydrocortisone Replacement Regimens in Adrenocorticotrophic Hormone Deficiency Pediatrics, July 1, 2007; 120(1): e164 - e171. [Abstract] [Full Text] [PDF]

				Joint LWPES/ESPE CAH Working Group Consensus Statement on 21-Hydroxylase Deficiency from The Lawson Wilkins Pediatric Endocrine Society and The European Society for Paediatric Endocrinology J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4048 - 4053. [Full Text] [PDF]